Arbutus Biopharma Corporation (ABUS) Ownership
ABUS ownership summary
as of October 17, 2026- Institutions
- 67.2% of shares outstanding
- Insiders
- 15.92% of shares outstanding
- Shares outstanding
- 153.3M
- Float
- 150.5M shares available to trade
- Short interest
- 38.47% 34.1M shares short
- Days to cover
- 5.03 short interest up 84.2% vs prior month
- Institutions 67.25%
- Insiders 15.92%
- Other investors 16.83%
ABUS top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Two Seas Capital LP | 12.11% | 18.6M | $78.3M | +6.0M (+47.4%) | March 31, 2026 |
| 2 | Morgan Stanley - Brokerage Accounts | 11.55% | 17.7M | $74.7M | −8.2M (−31.6%) | June 30, 2026 |
| 3 | Whitefort Capital Management, LP. | 10.30% | 15.8M | $66.7M | +863,376 (+5.8%) | June 30, 2026 |
| 4 | BlackRock Inc | 8.98% | 13.8M | $58.1M | +799,125 (+6.2%) | June 30, 2026 |
| 5 | State Street Corp | 5.13% | 7.9M | $33.2M | +1.5M (+24.1%) | June 30, 2026 |
| 6 | Rubric Capital Management LP | 4.91% | 7.5M | $31.8M | +906,548 (+13.7%) | June 30, 2026 |
| 7 | Vanguard Capital Management, LLC | 4.57% | 7.0M | $29.6M | +321,768 (+4.8%) | June 30, 2026 |
| 8 | Barclays PLC | 2.75% | 4.2M | $17.8M | −108,181 (−2.5%) | June 30, 2026 |
| 9 | Geode Capital Management, LLC | 2.69% | 4.1M | $17.4M | +345,885 (+9.2%) | June 30, 2026 |
| 10 | The Goldman Sachs Group Inc | 2.29% | 3.5M | $14.8M | +2.4M (+218.7%) | June 30, 2026 |
| 11 | Bank of America Corp | 1.73% | 2.6M | $11.2M | +962,569 (+57.2%) | June 30, 2026 |
| 12 | BlackBarn Capital Partners LP | 1.63% | 2.5M | $10.6M | — | June 30, 2026 |
| 13 | Legal & General Group PLC | 1.61% | 2.5M | $10.4M | +64,738 (+2.7%) | June 30, 2026 |
| 14 | Woodline Partners LP | 1.49% | 2.3M | $9.6M | +271,684 (+13.5%) | June 30, 2026 |
| 15 | Jefferies Financial Group Inc | 1.12% | 1.7M | $7.2M | −182,395 (−9.6%) | June 30, 2026 |
| 16 | Nomura Holdings Inc | 1.07% | 1.6M | $6.9M | +1.6M (0.0%) | June 30, 2026 |
| 17 | Vanguard Portfolio Management, LLC | 1.01% | 1.5M | $6.5M | +149,434 (+10.7%) | June 30, 2026 |
| 18 | Charles Schwab Investment Management Inc | 0.93% | 1.4M | $6.0M | +30,061 (+2.1%) | June 30, 2026 |
| 19 | Northern Trust Corp | 0.93% | 1.4M | $6.0M | +141,165 (+11.0%) | June 30, 2026 |
| 20 | Advisor Group Holdings, Inc. | 0.88% | 1.3M | $5.7M | −261 (−0.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 16.4M shares and 4 cut 8.5M.
ABUS top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 3.28% | 5.0M | $21.2M | — | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 2.66% | 4.1M | $17.2M | −47,040 (−1.1%) | September 30, 2026 |
| 3 | State Street® SPDR® S&P® Biotech ETF | 1.83% | 2.8M | $11.9M | −53,700 (−1.9%) | September 30, 2026 |
| 4 | Morgan Stanley Insight I | 1.78% | 2.7M | $11.5M | −1.1M (−28.8%) | June 30, 2026 |
| 5 | Fidelity Small Cap Index | 1.15% | 1.8M | $7.4M | +15,190 (+0.9%) | July 31, 2026 |
| 6 | Morgan Stanley Inst Inception I | 1.06% | 1.6M | $6.9M | −404,061 (−19.9%) | June 30, 2026 |
| 7 | iShares Russell 2000 Growth ETF | 0.99% | 1.5M | $6.4M | −1,925 (−0.1%) | September 30, 2026 |
| 8 | EQ/Morgan Stanley Small Cap Growth K | 0.90% | 1.4M | $5.8M | — | August 31, 2026 |
| 9 | iShares Biotechnology ETF | 0.81% | 1.2M | $5.3M | −9,432 (−0.8%) | September 30, 2026 |
| 10 | Vanguard Russell 2000 ETF | 0.60% | 923K | $3.9M | +20,622 (+2.3%) | August 31, 2026 |
| 11 | Schwab US Small-Cap ETF™ | 0.54% | 825K | $3.5M | +558 (+0.1%) | September 30, 2026 |
| 12 | Fidelity Extended Market Index | 0.51% | 782K | $3.3M | −4,202 (−0.5%) | August 31, 2026 |
| 13 | First Trust Dow Jones Sel MicroCap ETF | 0.45% | 687K | $2.9M | — | September 30, 2026 |
| 14 | MS INVF Global Insight Z | 0.43% | 656K | $2.8M | — | June 30, 2026 |
| 15 | MS INVF Global Endurance Z USD Acc | 0.40% | 611K | $2.6M | +305,245 (+99.7%) | June 30, 2026 |
| 16 | UBS (Lux) EF Biotech (USD) P-acc | 0.38% | 578K | $2.4M | — | June 30, 2026 |
| 17 | Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 0.35% | 535K | $2.3M | — | September 30, 2026 |
| 18 | Janus Henderson Small Cap Gr Alpha ETF | 0.34% | 522K | $2.2M | +22,260 (+4.5%) | September 30, 2026 |
| 19 | iShares Micro-Cap ETF | 0.33% | 506K | $2.1M | −3,491 (−0.7%) | September 30, 2026 |
| 20 | Vanguard Health Care ETF | 0.28% | 435K | $1.8M | +1,896 (+0.4%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ABUS insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2021-02-09 | Michael J Mcelhaugh | Sell | $5.00 | 20,000 | $100,000 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ABUS shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ABUS
Institutional investors own 67.2% of Arbutus Biopharma's shares and insiders 15.92%. The largest holder is Two Seas Capital LP with 12.11% of the shares (18.6M), as of March 31, 2026. Among the top 20 institutions, 15 added shares and 4 reduced their stake in the latest filings. Short interest is 38.47% of the float, or 5.03 days of average trading volume. The share count rose 534.3% since 2014.
Related: ABUS analyst forecast, ABUS key metrics. See the ABUS stock overview for the latest quote and news.
ABUS ownership FAQ
Who owns the most Arbutus Biopharma stock?
The largest shareholders of Arbutus Biopharma are Two Seas Capital LP (12.11%), Morgan Stanley - Brokerage Accounts (11.55%), Whitefort Capital Management, LP. (10.30%), BlackRock Inc (8.98%), State Street Corp (5.13%).
What percentage of Arbutus Biopharma is owned by institutions?
Institutions hold 67.2% of Arbutus Biopharma's shares outstanding; insiders hold 15.92%.
Which funds own Arbutus Biopharma?
The largest fund holders of Arbutus Biopharma are Vanguard MStar Total Stk Mkt Idx Invest (3.28%), iShares Russell 2000 ETF (2.66%), State Street® SPDR® S&P® Biotech ETF (1.83%), Morgan Stanley Insight I (1.78%), Fidelity Small Cap Index (1.15%).
What is Arbutus Biopharma's short interest?
34.1M shares of Arbutus Biopharma were sold short, 38.47% of the float; at the average daily volume it would take 5.03 days to cover.
Are insiders buying or selling Arbutus Biopharma?
Of the latest 1 reported insider transactions in Arbutus Biopharma (since February 9, 2021), 0 were purchases and 1 were sales.
How many shares of Arbutus Biopharma are outstanding?
Arbutus Biopharma has 153.3M shares outstanding, of which 150.5M are in the public float.